With decades of leadership experience in the life science industry, our team fosters an ethos of innovation to develop regenerative medicine therapies aimed at treating a range of serious liver diseases. 

Jonathan Lieber

President & Chief Financial Officer

Thomas Jurgensen

General Counsel

Jeffrey N. Miner

Chief Scientific Officer